Showing results (31-40 of 232) with videos related to

Sort By:
Pageof 24
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 5, 2020
Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing's DiseaseValentina Guarnotta, Antonio Prinzi, Maria Pitrone, et al.
Heliyon|September 16, 2024
The promising approach of 3D bioprinting for diabetic foot ulcer treatment: A concise review of recent developmentsMattia Biondo, Laura Tomasello, Carla Giordano, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 12, 2018
Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective StudyAlessandro Ciresi, Enrica Vigneri, Stefano Radellini, et al.
International Journal of Molecular Sciences|May 28, 2022
Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine SystemValentina Guarnotta, Roberta Amodei, Francesco Frasca, et al.
International Journal of Molecular Sciences|August 12, 2023
Irisin: A Possible Marker of Adipose Tissue Dysfunction in ObesityLaura Tomasello, Maria Pitrone, Valentina Guarnotta, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|October 3, 2021
Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognosticationCarla Giordano, Marco Francone, Giulia Cundari, et al.
International Journal of Endocrinology|April 18, 2022
Metabolic Profile in a Cohort of Young Sicilian Patients with Klinefelter's Syndrome: The Role of IrisinStefano Radellini, Valentina Guarnotta, Vincenzo Sciabica, et al.
Frontiers in Endocrinology|July 24, 2018
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of TreatmentFrancesco Ferraù, Adriana Albani, Alessandro Ciresi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 16, 2017
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective StudyAlessandro Ciresi, Enrica Vigneri, Stefano Radellini, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 30, 2021
One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes MellitusStefano Radellini, Enrica Vigneri, Valentina Guarnotta, et al.
Pageof 24